Oral formulation and suspension of an oncology drug
Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptably hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
1. A powder for oral suspension, comprising: sonidegib, or a pharmaceutically acceptable salt thereof, in powder form, and a filler comprising microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide, sucrose, dextrose, starch, mannitol, dextrose, or a mixture thereof, a glident comprising fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, colloidal silicon dioxide, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, magnesium lauryl sulfate, and magnesium oxide, or a mixture of two or more thereof, a lubricant comprising magnesium stearate, colloidal silicon dioxide, talc, calcium stearate, stearic acid, PEG, glyceryl monostearate, potassium benzoate, sodium stearyl fumarate, glyceryl behenate, mineral oil, or a mixture of two or more thereof, or a combination of two or more of said filler, glident and lubricant.
2. The powder of claim 1 , comprising the filler, the glident and the lubricant.
3. The powder of claim 1 , wherein the filler comprises microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide or a mixture thereof.
4. The powder of claim 1 , wherein the filler comprises microcrystalline cellulose, the glident comprises colloidal silicon dioxide, and the lubricant comprises magnesium stearate.
5. The powder of claim 4 , wherein the sonidegib is present in the powder in the form of a phosphate salt.
6. The powder of claim 2 , wherein weight percentages of the sonidegib or the pharmaceutically acceptable salt thereof, the filler, the glident, and the lubricant are within ranges of 25-35%, 55-75%, 0.3-0.7%, and 0.5-1.5%, respectively, relative to the total weight of the powder.
7. The powder of claim 6 , wherein the weight percentages of the sonidegib, the filler, the glident, and the lubricant are about 30%, about 68%, about 0.5%, and about 1%, respectively, relative to the total weight of the powder.
8. A pharmaceutical kit comprising: a) a powder for oral suspension, wherein the powder for oral suspension comprises sonidegib, or a pharmaceutically acceptable salt in powder form, and a filler comprising microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide, sucrose, dextrose, starch, mannitol, dextrose, or a mixture thereof, a glident comprising fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, colloidal silicon dioxide, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, magnesium lauryl sulfate, and magnesium oxide, or a mixture of two or more thereof, a lubricant comprising magnesium stearate, colloidal silicon dioxide, talc, calcium stearate, stearic acid, PEG, glyceryl monostearate, potassium benzoate, sodium stearyl fumarate, glyceryl behenate, mineral oil, or a mixture of two or more thereof, or a combination of two or more of said filler, glident and lubricant; and b) an oily vehicle, wherein the powder and the oily vehicle are separately disposed in the kit.
9. The pharmaceutical kit of claim 8 , wherein the powder comprises the sonidegib or a pharmaceutically acceptable salt thereof, the filler, the glident and the lubricant.
10. The pharmaceutical kit of claim 8 , wherein the filler comprises microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide or a mixture of two or more thereof.
11. The pharmaceutical kit of claim 8 , wherein the filler comprises microcrystalline cellulose, the glident comprises colloidal silicon dioxide, and the lubricant comprises magnesium stearate.
12. The pharmaceutical kit of claim 11 , wherein the sonidegib is present in the powder in the form of a phosphate salt.
13. The pharmaceutical kit of claim 9 , wherein weight percentages of the sonidegib or the pharmaceutically acceptable salt thereof, the filler, the glident, and the lubricant are within ranges of 25-35%, 55-75%, 0.3-0.7%, and 0.5-1.5%, respectively, relative to the total weight of the powder disposed in said first container.
14. The pharmaceutical kit of claim 13 , wherein the weight percentages of the sonidegib, the filler, the glident, and the lubricant are about 30%, about 68%, about 0.5%, and about 1%, respectively, relative to the total weight of the powder.
15. The pharmaceutical kit of claim 8 , wherein the oily vehicle comprises a medium fatty acid chain triglyceride.
16. The pharmaceutical kit of claim 15 , wherein the medium fatty acid chain triglyceride is obtained from coconut oil, palm kernel oil or camphor tree drupes.
17. The pharmaceutical kit of claim 15 , wherein the medium chain triglyceride comprises 55% triglycerides of C8 fatty acids and 45% triglycerides of C10 fatty acids.
18. The pharmaceutical kit of claim 8 , wherein the oily vehicle is present in said second container in a volume of about 50 ml to about 100 ml.
19. The pharmaceutical kit of claim 18 , wherein the volume of the oily vehicle is about 80 ml.
20. The pharmaceutical kit of claim 8 , wherein amount of sonidegib or pharmaceutically acceptable salt thereof, and volume of the oily vehicle provide, upon dispersing the powder into the oily vehicle, an oral suspension that comprises about 50 mg/mL of sonidegib.
21. The pharmaceutical kit of claim 8 , further comprising a flavor or sweetener.
22. The pharmaceutical kit of claim 8 , which comprises a first container and a second container, and wherein the powder is contained in the first container and the oily vehicle is contained in the second container.
23. The pharmaceutical kit of claim 8 , further comprising a dispensing syringe, a dosing syringe or a dispensing syringe and a dosing syringe.
24. A method of treating a Hedgehog-dependent brain tumor, comprising administering to a patient in need thereof a composition comprising a) sonidegib, or a pharmaceutically acceptable salt thereof, in powder form, b) a filler comprising microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide, sucrose, dextrose, starch, mannitol, dextrose, or a mixture thereof, c) a glident comprising fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, colloidal silicon dioxide, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, magnesium lauryl sulfate, and magnesium oxide, or a mixture of two or more thereof, d) a lubricant comprising magnesium stearate, colloidal silicon dioxide, talc, calcium stearate, stearic acid, PEG, glyceryl monostearate, potassium benzoate, sodium stearyl fumarate, glyceryl behenate, mineral oil, or a mixture of two or more thereof, or a combination of two or more of said filler, glident and lubricant, and e) an oily vehicle comprising a medium fatty acid chain triglyceride, wherein said composition is in the form of a suspension.
25. The method of claim 24 , wherein the Hedgehog-dependent brain tumor is medulloblastoma.
26. The method of claim 24 , wherein the patient is a toddler or child from 0 to 19 years of age.